Alpha Thalassemia Treatment Market 2019-2027 | Size, Share, Opportunities and Forecast | Credence Research

The global market for alpha thalassemia treatment was estimated at USD 526.1 million in 2018 and is expected to reach USD 965.4 million by 2027, expanding to CAGR 7.1% from 2019 to 2027.

SANJOSE, United States - June 19, 2019 /MarketersMedia/ —

According to the latest report published by Credence Research, Inc. “Alpha Thalassemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2019-2027,” the global alpha thalassemia treatment market was valued at USD 526.1 Mn in 2018, and is expected to reach USD 965.4 Mn by 2027, expanding at a CAGR of 7.1% from 2019 to 2027.

Market Insights

Alpha thalassemia causes due to deficiency or absence of alpha globin chains results in alpha thalassemia which is asymptomatic with general hematologic findings and gains silent carrier status. The alpha thalassemia is categorized as alpha thalassemia, hemoglobin H-constant spring, silent carrier, hemoglobin H disease, alpha thalassemia trait, and alpha thalassemia major. Alpha thalassemia is caused specifically due to two different genes such as HBA1 and HBA2 genes. Alpha thalassemia is found worldwide in several regions but most commonly in the Southeast Asia, Middle East, and certain Mediterranean countries. According to The California Newborn Screening Program, the high birth prevalence rate of alpha thalassemia major (ATM) was identified in immigrant women from Vietnam, China, and Philippines which reflects the migration patterns and its effects in this region.

Browse the full report Alpha Thalassemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2019-2027 report at

In 2018, Deferasirox was identified as the largest drug segment in alpha thalassemia treatment market due to key factors such as it is currently the only USFDA approved drug for alpha thalassemia treatment, and increasing awareness related to thalassemia in medical practitioners & patients from developing countries. However, folic acid plays crucial role in alpha thalassemia management which makes it one of the crucial element of treatment regimen.

In 2018, North America was identified as the largest alpha thalassemia treatment market due to increasing entry of immigrants in the United States and Canada specifically from Asia and rising awareness related to alpha thalassemia in patients as well as medical practitioners is expected to assist the growth in the near future. However, Middle East & Africa is identified as the fastest growing alpha thalassemia market due to high prevalence of alpha thalassemia, and rising awareness related to rare hematological diseases.

Market Competition Assessment:

The alpha thalassemia treatment market is growing gradually and key companies operating in this market are developing treatments that are safe and target-specific. The major companies available in the global market are bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, Shire Plc. (Takeda Pharmaceuticals), Incyte Corporation, Kiadis Pharma, and GlaxoSmithKline among others.

Key Market Movements:

Rising awareness and prevalence related to alpha thalassemia treatment & diagnosis expected to assist the market growth
Incessant growth in research & development of alpha thalassemia treatment will assist the growth in demand for safe & efficient treatment options
Mounting diagnosis rate related to developing countries will increase the demand for alpha thalassemia treatment market
Strong drug pipeline anticipated to increase the CAGR of the overall market in the near future

Request For The Sample:

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary

Chapter 3. Global Alpha Thalassemia Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2018

Chapter 4. Global Alpha Thalassemia Treatment Market, by Type of Drugs, 2017 – 2027 (US$ Mn)
4.1. Overview
4.2. Folic Acid
4.3. Deferasirox
4.4. Deferiprone
4.5. Hydroxyurea

Chapter 5. Global Alpha Thalassemia Treatment Market, Pipeline Analysis

Chapter 6. Global Alpha Thalassemia Treatment Market, by Geography, 2017 – 2027 (US$ Mn)

Chapter 7. Company Profiles
7.1. GlaxoSmithKline Plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Bellicum Pharmaceuticals
7.3. Novartis AG
7.4. Acceleron Pharma
7.5. Johnson & Johnson
7.6. Merck & Co Inc.
7.7. Alnylam Pharmaceuticals Inc.
7.8. Calimmune Inc.
7.9. Editas Medicine Inc.
7.10. Gilead Sciences Inc.
.................toc continued

Browse the full report Alpha Thalassemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2019-2027 report at

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290

Source URL:

Source: MarketersMedia

Release ID: 526750

Latest News

VW, Ford team up to make autonomous, electric vehicles

Jul 18, 2019

NEW YORK — Volkswagen will invest $2.6 billion into a Pittsburgh autonomous vehicle company that's mostly owned by Ford as the automakers who were once rivals deepen their partnership to develop driverless and electric vehicles in an ultra-competitive landscape. The two automakers will become equal owners of Argo AI, and they plan to put autonomous vehicles on the roads in the U.S. and Europe as early as 2021, the companies said Friday. The deal also includes a plan for Ford to use VW's electric vehicle platform to build zero-emissions cars for the European market starting in 2023. Auto companies have...

The Latest: Experts like what they see in Ford, VW tie-up

Jul 18, 2019

NEW YORK — The Latest on Ford's alliance with Volkswagen (all times local): 9:25 a.m. Auto industry watchers say Ford and Volkswagen have the right idea with their new partnership to develop autonomous and electronic vehicle technology. The companies on Friday announced Friday that Volkswagen will invest $2.6 billion into a Pittsburgh autonomous vehicle company that's mostly owned by Ford. Jessica Caldwell, executive director industry insights for the auto pricing site, says the deal should help both companies and is an example of what's needed in the business to share enormous capital costs. She says both automakers are facing...

Trump applauds far-right social media provocateurs

Jul 18, 2019

WASHINGTON — President Donald Trump used a White House conference Thursday to applaud far-right social media provocateurs even as he conceded that some of them are extreme in their views. Trump, who has weaponized social media to eviscerate opponents and promote himself, led a "social media summit" of like-minded critics of Big Tech, excluding representatives from the very platforms he exploits. The president used the event to air grievances over his treatment by Big Tech, but also to praise some of the most caustic voices on the right, who help energize Trump's political base. "Some of you guys are out...

Fresh from the lab: Startups make meat that avoids slaughter

Jul 18, 2019

EMERYVILLE, Calif. — Uma Valeti slices into a pan-fried chicken cutlet in the kitchen of his startup, Memphis Meats. He sniffs the tender morsel on his fork before taking a bite. He chews slowly, absorbing the taste. "Our chicken is chicken ... you've got to taste it to believe it," Valeti says. This is no ordinary piece of poultry. No chicken was raised or slaughtered to harvest the meat. It was produced in a laboratory by extracting cells from a chicken and feeding them in a nutrient broth until the cell culture grew into raw meat. Memphis Meats, based in...

Oklahoma judge denies motion to end case against drugmaker

Jul 18, 2019

OKLAHOMA CITY — An Oklahoma judge decided Monday the state's ongoing opioid drug lawsuit against consumer products giant Johnson & Johnson can move forward, rejecting the company's argument that the state failed to prove its public-nuisance claim. District Judge Thad Balkman denied Johnson & Johnson lawyers' motion asking him to end the case mid-trial and rule in favor of the New Brunswick, New Jersey-based company and its subsidiaries, including Janssen Pharmaceuticals Inc. The defendants filed the motion last week after the state rested its case. The trial began May 28. Company attorneys had argued the state's case is an inappropriate...

Emporium Post fulfils the need to know all things about consumers and how businesses can take this opportunity to reach their own customers.

Contact us:

Join our mailing list now!